143 related articles for article (PubMed ID: 32496433)
1. SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.
Kambara T; Amatya VJ; Kushitani K; Suzuki R; Fujii Y; Kai Y; Miyata Y; Okada M; Takeshima Y
Am J Surg Pathol; 2020 Sep; 44(9):1259-1265. PubMed ID: 32496433
[TBL] [Abstract][Full Text] [Related]
2. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
Chapel DB; Hirsch MS
Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
[TBL] [Abstract][Full Text] [Related]
3. Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma.
Naso JR; Cheung S; Ionescu DN; Churg A
Am J Surg Pathol; 2021 Sep; 45(9):1245-1251. PubMed ID: 33782226
[TBL] [Abstract][Full Text] [Related]
4. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Kushitani K; Kai Y; Suzuki R; Miyata Y; Okada M; Takeshima Y
Mod Pathol; 2018 May; 31(5):809-815. PubMed ID: 29327712
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
6. Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma.
Kuraoka M; Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Nishisaka T; Sueda T; Takeshima Y
Am J Surg Pathol; 2017 Aug; 41(8):1045-1052. PubMed ID: 28394802
[TBL] [Abstract][Full Text] [Related]
7. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
[TBL] [Abstract][Full Text] [Related]
8. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
9. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
Kai Y; Amatya VJ; Kushitani K; Kambara T; Suzuki R; Tsutani Y; Miyata Y; Okada M; Takeshima Y
Histopathology; 2019 Mar; 74(4):545-554. PubMed ID: 30329165
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Takeshima Y; Kohno H; Kushitani K; Yamada T; Morimoto C; Inai K
Histopathology; 2009 Jul; 55(1):10-9. PubMed ID: 19614762
[TBL] [Abstract][Full Text] [Related]
11. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
Nakagiri T; Amatya VJ; Kushitani K; Kambara T; Aoe K; Endo I; Miyata Y; Okada M; Takeshima Y
Am J Surg Pathol; 2024 Feb; 48(2):140-149. PubMed ID: 37899530
[TBL] [Abstract][Full Text] [Related]
12. Epithelioid angiosarcoma at chest wall which needs to be carefully distinguished from malignant mesothelioma: report of a rare case.
Fan C; Liu Y; Lin X; Han Y; He A; Wang E
Int J Clin Exp Pathol; 2014; 7(12):9056-60. PubMed ID: 25674287
[TBL] [Abstract][Full Text] [Related]
13. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary adenocarcinoma simulating malignant mesothelioma.
Tang P; Vatsia SK; Teichberg S; Kahn E
Arch Pathol Lab Med; 2001 Dec; 125(12):1598-600. PubMed ID: 11735699
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
Ordóñez NG; Sahin AA
Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
[TBL] [Abstract][Full Text] [Related]
17. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
18. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
[TBL] [Abstract][Full Text] [Related]
19. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]